Standout Papers

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of... 2018 2026 2020 2023 307
  1. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial (2018)
    Zhi‐Wei Lai, Ryan L. Kelly et al. The Lancet

Immediate Impact

2 from Science/Nature 60 standout
Sub-graph 1 of 23

Citing Papers

Energy metabolism in health and diseases
2025 Standout
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
2025 Standout
6 intermediate papers

Works of Maha Dawood being referenced

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
2018 Standout
Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus
2013
and 1 more

Author Peers

Author Last Decade Papers Cites
Maha Dawood 375 514 110 246 7 861
Hajra Tily 372 479 105 229 7 771
Edward Doherty 279 448 85 279 12 791
Akihiko Okahara 281 435 158 264 13 948
Phil Ruiz 288 530 99 258 12 840
Syuichi Nakatsuru 251 519 215 335 10 1.0k
Konstantin N. Konstantinov 388 376 66 325 7 923
Minggao Liang 586 304 59 336 18 1.0k
Kelly A. Remedios 95 431 120 227 8 767
Susan W. Burriss 590 452 70 130 10 1.0k
Stacy L. Musone 134 344 69 289 10 999

All Works

Loading papers...

Rankless by CCL
2026